EGFR and non-small cell lung carcinoma: Due to the heterogeneity and low incidence of uncommon EGFR alterations, as well as the lack of large-scale randomized clinical trials, clinical outcomes of diverse treatment modalities for advanced NSCLC harboring uncommon EGFR alterations have not been fully elucidated.